ImmunityBio, Inc. (IBRX) Earnings History
Net Loss13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
ImmunityBio, Inc. (IBRX) Earnings Overview
As of June 22, 2026, ImmunityBio, Inc. (IBRX) reported trailing twelve-month net income of -$855M, reflecting +38.7% year-over-year growth. The company earned $-0.83 per diluted share over the past four quarters, with a net profit margin of -310.2%.
Looking at the long-term picture, IBRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
ImmunityBio, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NKTR (-$158M net income, -297.1% margin), FATE (-$130M net income, -2051.1% margin), CRIS (-$21M net income, -80.3% margin), IBRX has room to improve margins relative to the peer group. Compare IBRX vs NKTR →
IBRX Earnings vs Peers
Earnings metrics vs comparable public companies
IBRX Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$351M | +15.0% | -$256M | $-0.38 | -310.2% | -226.0% |
| 2024 | -$414M | +29.1% | -$344M | $-0.62 | -2804.8% | -2334.2% |
| 2023 | -$583M | -40.0% | -$362M | $-1.15 | -93761.4% | -58239.5% |
| 2022 | -$417M | -20.1% | -$351M | $-1.04 | -173569.6% | -146374.2% |
| 2021 | -$347M | -56.3% | -$330M | $-0.89 | -37129.6% | -35361.9% |
| 2020 | -$222M | -237.2% | -$221M | $-0.59 | -36669.6% | -36509.1% |
| 2019 | -$66M | +31.6% | -$67M | $-0.42 | -152997.7% | -155597.7% |
| 2018 | -$96M | +0.2% | -$98M | $-0.30 | -204736.2% | -209338.3% |
| 2017 | -$96M | +20.2% | -$99M | $-0.30 | -214273.3% | -220266.7% |
| 2016 | -$121M | +49.0% | -$125M | $-0.37 | -274565.9% | -282954.5% |
| 2015 | -$237M | -3712.6% | -$239M | $-0.73 | -100371.2% | -101218.6% |
| 2014 | -$6M | -203.5% | -$6M | $-0.02 | -969.3% | -969.1% |
| 2013 | -$2M | - | -$2M | $-0.01 | -341.2% | -378.2% |
Download Data
Export IBRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IBRX — Frequently Asked Questions
Quick answers to the most common questions about buying IBRX stock.
What is IBRX earnings per share (EPS)?
IBRX trailing twelve-month (TTM) diluted EPS is $-0.83, reflecting +38.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is ImmunityBio, Inc.'s net income?
ImmunityBio, Inc. (IBRX) trailing twelve-month net income is $-855M as of 2025. Earnings grew +38.7% year-over-year.
Is IBRX profitable?
IBRX is not currently profitable on a TTM basis, reporting a net loss of $-855M. Net margin is -310.2%. Investors should monitor for a return to profitability.
What is IBRX's earnings growth rate?
IBRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are IBRX's profit margins?
ImmunityBio, Inc. net profit margin is -310.2%, operating margin is -226.0%, and gross margin is +99.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is IBRX growing earnings?
Yes, IBRX earnings are accelerating — EPS growth of +38.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-855M. Earnings momentum is strengthening.
What was IBRX's best earnings year?
ImmunityBio, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2013. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were IBRX's earnings last quarter?
IBRX's most recent reported quarter was Q1 2026. Net income was $-633M with diluted EPS of $-0.62. For a full breakdown of all quarters, see the quarterly earnings table on this page.